Smythe MA, Mattson JC, Koerber JM (2002) The heparin anti- Xa therapeutic range: are we there yet? Chest 121:303-304Smythe MA, Mattson JC. The heparin anti-Xa therapeutic range. Are we there yet? Chest 2002;121:303.Smythe MA, Koerber JL, Mattson JC. The heparin anti-Xa therapeutic ...
To describe the successful use of high-dose enoxaparin therapy (1.5 mg/kg subcutaneously twice daily) to attain a therapeutic anti-factor Xa (anti-Xa) level in a cancer patient with heparin resistance.A proven heparin-resistant patient with venous thromboembolism (VTE) and lung cancer who require...
We established an aPTT heparin therapeutic range (HTR) corresponding to therapeutic anti-Xa levels for continuous intravenous UFH administration, and used appropriate monitoring to determine if an adequate dose of UFH was applied. A total of 134ex vivosamples were obtained from 71 patients with a ...
Eighty treatment courses with interpretable anti-Xa levels were analyzed. Mean patient age was 6.5 years. Mean enoxaparin dose was 1.10 mg/kg q12h. Correlation between initial dosing and anti-Xa level was poor; R2 = 0.0307 and 0.0237 for patients > 2 months with and without cardiac...
Changing a heparin order set to utilize anti Xa monitoring and to improve time to therapeutic anticoagulationMoyers, PTatro, JFerguson, TBall, JTimmons, C
We therefore compared DNase1 therapy to a conventional anti-thrombotic therapy, comprised of low molecular weight heparin and tissue plasminogen activator (tPA). Material and Methods Study design The study was approved by the Hamburg State Administration for animal research (Protocol number: 88/14)....
NOVEL ANTI-CANCER THERAPEUTIC COMPOUNDS FIELD OF THE INVENTION The present invention is of therapeutic compounds for cancer, and in particular, of therapeutic compounds which block the ability of cytokines and chemokines to promote metastasis of malignant cells, and which are heparin and heparan-sulfate...
R. et al. Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis. Thromb. Res. 100, 73–79 (2000). CAS PubMed Google Scholar ...
Biodegradation of the polymers resulted in free heparin available, a well-known anti-coagulant. Furthermore, macrophage uptake of RBC-absorbed NPs was reduced in vitro, suggesting that incorporating NPs onto cells could possibly help to evade recognition by the immune system (Figure 6C); especially...
The heparin/ATIII complex has the highest affinity for Factor Xa and thrombin which are common to both the intrinsic and extrinsic clotting pathways involved as the last two steps of the clotting cascade that results in the conversion of fibrinogen to fibrin. The additional antibacterial and anti...